Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in:

24-06-2024 | Cardiac Diagnostics | Review

The Emerging Specialty of Cardio-Rheumatology

Authors: Malek Nayfeh, Helene DiGregorio, Jean Michel Saad, Mouaz Al-Mallah, Mahmoud Al Rifai

Published in: Current Atherosclerosis Reports | Issue 9/2024

Login to get access

Abstract

Purpose of Review

In this review, we aimed to summarize the different aspects of the field of cardio-rheumatology, the role of the cardio-rheumatologist, and future research in the field.

Recent Findings

Cardio-rheumatology is an emerging subspecialty within cardiology that focuses on addressing the intricate relationship between systemic inflammation and cardiovascular diseases. It involves understanding the cardiovascular impact of immune-mediated inflammatory diseases on the heart and vascular system.

Summary

A cardio-rheumatologist’s role is multifaceted. First, they should understand the cardiac manifestations of rheumatological diseases. They should also be knowledgeable about the different immunotherapies available and side effects. Additionally, they should know how to utilize imaging modalities, either for diagnosis, prognosis, or treatment monitoring. This field is constantly evolving with new research on both treatment and imaging of the effects of inflammation on the cardiovascular system.
Literature
1.
2.
Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol. 2018;2(1):10.PubMedPubMedCentralCrossRef
3.
Shoenfeld Y, et al. Accelerated atherosclerosis in Autoimmune Rheumatic diseases. Circulation. 2005;112(21):3337–47.PubMedCrossRef
4.
5.
Zhang K, et al. Interleukin 6 destabilizes atherosclerotic plaques by downregulating prolyl-4-hydroxylase α1 via a mitogen-activated protein kinase and c-Jun pathway. Arch Biochem Biophys. 2012;528(2):127–33.PubMedCrossRef
6.
Gulick T, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989;86(17):6753–7.PubMedPubMedCentralCrossRef
7.
Yokoyama T, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1993;92(5):2303–12.PubMedPubMedCentralCrossRef
8.
Yu X, Kennedy RH, Liu SJ. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem. 2003;278(18):16304–9.PubMedCrossRef
9.
10.
Bansal SS, et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail. 2017;10(3):e003688.PubMedPubMedCentralCrossRef
11.
Zhang H, Dhalla NS. The role of pro-inflammatory cytokines in the Pathogenesis of Cardiovascular Disease. Int J Mol Sci, 2024. 25(2).
12.
Scarpioni R, Ricardi M, Albertazzi V. Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage. World J Nephrol. 2016;5(1):66–75.PubMedPubMedCentralCrossRef
13.
Chiabrando JG, et al. Management of Acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(1):76–92.PubMedCrossRef
14.
Asopa S, et al. Non-bacterial thrombotic endocarditis. Eur J Cardiothorac Surg. 2007;32(5):696–701.PubMedCrossRef
15.
16.
Aviña-Zubieta JA, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–7.PubMedCrossRef
17.
Villa-Forte A, Mandell BF. [Cardiovascular disorders and rheumatic disease]. Rev Esp Cardiol. 2011;64(9):809–17.PubMedCrossRef
18.
Roman MJ, Salmon JE. Cardiovascular manifestations of rheumatologic diseases. Circulation. 2007;116(20):2346–55.PubMedCrossRef
19.
Hara KS, et al. Rheumatoid pericarditis: clinical features and survival. Med (Baltim). 1990;69(2):81–91.CrossRef
20.
Cathcart ES, Spodick DH. Rheumatoid heart disease. A study of the incidence and nature of cardiac lesions in rheumatoid arthritis. N Engl J Med. 1962;266:959–64.PubMedCrossRef
21.
Gonzalez-Juanatey C, et al. Echocardiographic and doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2004;33(4):231–8.PubMedCrossRef
22.
Guedes C, et al. Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum. 2001;45(2):129–35.PubMedCrossRef
23.
Di Franco M, et al. Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis. 2000;59(3):227–9.PubMedCrossRef
24.
Nomeir AM, Turner RA, Watts LE. Cardiac involvement in rheumatoid arthritis. Followup study. Arthritis Rheum. 1979;22(6):561–4.PubMedCrossRef
25.
Chung CP, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52(10):3045–53.PubMedCrossRef
26.
Gonzalez-Juanatey C, et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Med (Baltim). 2003;82(6):407–13.CrossRef
27.
Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med, 2006. 144(4): p. 249–56.
28.
Grisar J, et al. Depletion of endothelial progenitor cells in the Peripheral blood of patients with rheumatoid arthritis. Circulation. 2005;111(2):204–11.PubMedCrossRef
29.
Solomon DH, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303–7.PubMedCrossRef
30.
Weber B, et al. Relationship between risk of atherosclerotic Cardiovascular Disease, inflammation, and coronary microvascular dysfunction in rheumatoid arthritis. J Am Heart Assoc. 2022;11(11):e025467.PubMedPubMedCentralCrossRef
31.
Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997;24(3):445–51.PubMed
32.
Lebowitz WB. The heart in rheumatoid arthritis (rheumatoid disease). A clinical and pathological study of sixty-two cases. Ann Intern Med. 1963;58:102–23.PubMedCrossRef
33.
Radovits BJ, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(3):362–70.PubMedCrossRef
34.
Avina-Zubieta JA, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524–9.PubMedCrossRef
35.
Maradit-Kremers H, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402–11.PubMedCrossRef
36.
Al-Ewaidat OA, Naffaa MM. Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care. Clin Exp Med. 2024;24(1):30.PubMedPubMedCentralCrossRef
37.
Roldan CA, et al. Characterization of valvular heart disease in rheumatoid arthritis by transesophageal echocardiography and clinical correlates. Am J Cardiol. 2007;100(3):496–502.PubMedCrossRef
38.
Owlia M. R Clinical Spectrum of Connective Tissue Disorders Journal, Indian Academy of Clinical Medicine, 2006. 7.
39.
Crowson CS, et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum. 2005;52(10):3039–44.PubMedCrossRef
40.
Nicola PJ, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412–20.PubMedCrossRef
41.
Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116(5):305–11.PubMedCrossRef
42.
Montecucco C, et al. Impaired diastolic function in active rheumatoid arthritis. Relationship with disease duration. Clin Exp Rheumatol. 1999;17(4):407–12.PubMed
43.
Corrao S, et al. Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest. 1996;26(4):293–7.PubMedCrossRef
44.
Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.PubMedPubMedCentralCrossRef
45.
Gelfand JM, et al. The prevalence of psoriasis in African americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23–6.PubMedCrossRef
46.
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60(2):218–24.PubMedCrossRef
47.
48.
Abuabara K, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–92.PubMedPubMedCentralCrossRef
49.
Cea-Calvo L, et al. Underdiagnosis of Cardiovascular Risk factors in outpatients with Psoriasis followed at Hospital Dermatology offices: the PSO-RISK study. Acta Derm Venereol. 2016;96(7):972–3.PubMedCrossRef
50.
51.
Lerman JB, et al. Coronary plaque characterization in Psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017;136(3):263–76.PubMedPubMedCentralCrossRef
52.
Wu H, et al. Inflammatory bowel disease and cardiovascular diseases: a concise review. Eur Heart J Open. 2022;2(1):oeab029.PubMedCrossRef
53.
Cainzos-Achirica M, et al. Inflammatory bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review topic of the Week. J Am Coll Cardiol. 2020;76(24):2895–905.PubMedCrossRef
54.
Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol. 2018;25(15):1623–31.PubMedCrossRef
55.
Feng W et al. Inflammatory bowel Disease and Risk of Ischemic Heart Disease: an updated Meta-analysis of Cohort studies. J Am Heart Assoc, 2017. 6(8).
56.
Rungoe C, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62(5):689–94.PubMedCrossRef
57.
Kristensen SL, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death–a Danish nationwide cohort study. PLoS ONE. 2013;8(2):e56944.PubMedPubMedCentralCrossRef
58.
Ha C, et al. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009;104(6):1445–51.PubMedCrossRef
59.
Fumery M, et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014;8(6):469–79.PubMedCrossRef
60.
61.
Hillerdal G, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130(1):29–32.PubMed
62.
Birnie DH, et al. Cardiac manifestations of sarcoidosis: diagnosis and management. Eur Heart J. 2017;38(35):2663–70.PubMed
63.
Iwai K, et al. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn. 1993;43(7–8):377–85.PubMed
64.
65.
Hu X, et al. Causes of death in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):275–80.PubMed
66.
67.
Nordenswan HK, et al. Outcome of Cardiac Sarcoidosis presenting with high-Grade Atrioventricular Block. Circ Arrhythm Electrophysiol. 2018;11(8):e006145.PubMedCrossRef
68.
Ekström K, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019;40(37):3121–8.PubMedCrossRef
69.
Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–23.PubMedCrossRef
70.
Kandolin R, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624–32.PubMedCrossRef
71.
Taylor T, et al. Causes of death among individuals with systemic lupus erythematosus by race and ethnicity: a Population-based study. Arthritis Care Res (Hoboken). 2023;75(1):61–8.PubMedCrossRef
72.
Yafasova A, et al. Long-Term Cardiovascular outcomes in systemic Lupus Erythematosus. J Am Coll Cardiol. 2021;77(14):1717–27.PubMedCrossRef
73.
Gustafsson JT, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14(2):R46.PubMedPubMedCentralCrossRef
74.
Papazoglou N, et al. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology (Oxford). 2024;63(1):50–7.PubMedCrossRef
75.
Nojima J, et al. Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2008;47(5):684–9.PubMedCrossRef
76.
Nuttall SL, et al. Cardiovascular risk in systemic lupus erythematosus–evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford). 2003;42(6):758–62.PubMedCrossRef
77.
Greisman SG, et al. Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardiolipin antibody. Arch Intern Med. 1991;151(2):389–92.PubMedCrossRef
78.
Apte M, et al. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort (LV). [corrected]. Rheumatology (Oxford). 2008;47(3):362–7.PubMedCrossRef
79.
Tanwani J, et al. Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies. Lupus. 2018;27(8):1296–302.PubMedCrossRef
80.
Tincani A, et al. Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology (Oxford). 2006;45(Suppl 4):piv8–13.CrossRef
81.
Klein AL, et al. Phase 3 trial of Interleukin-1 trap rilonacept in recurrent Pericarditis. N Engl J Med. 2021;384(1):31–41.PubMedCrossRef
82.
Mohammadi Kebar Y, et al. Libman-Sacks endocarditis in patients with systemic lupus erythematosus with secondary antiphospholipid syndrome. Casp J Intern Med. 2019;10(3):339–42.
83.
Gumireddy SR, et al. Systemic Lupus Erythematosus presenting as constrictive pericarditis. Circ Cardiovasc Imaging. 2020;13(9):e010254.PubMedCrossRef
84.
Chatre C, et al. Cardiac complications attributed to Chloroquine and Hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919–31.PubMedCrossRef
85.
Jones PH, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004;26(9):1388–99.PubMedCrossRef
86.
Ballantyne CM, et al. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme a reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88(3):265–9.PubMedCrossRef
87.
Tousoulis D, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151–7.PubMedCrossRef
88.
89.
Albert MA, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64–70.PubMedCrossRef
90.
Sparrow CP, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21(1):115–21.PubMedCrossRef
91.
Vernaglione L, et al. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis. 2004;43(3):471–8.PubMedCrossRef
92.
Nakagomi A, et al. Differential effects of atorvastatin and Pitavastatin on inflammation, insulin resistance, and the carotid intima-media thickness in patients with Dyslipidemia. J Atheroscler Thromb. 2015;22(11):1158–71.PubMedCrossRef
93.
Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRef
94.
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–54.PubMedCrossRef
95.
Choi HK, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173–7.PubMedCrossRef
96.
van Halm VP, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006;8(5):R151.PubMedPubMedCentralCrossRef
97.
98.
Ridker PM, et al. Low-dose methotrexate for the Prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62.PubMedCrossRef
99.
Imazio M, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012–6.PubMedCrossRef
100.
Imazio M, et al. Investigation on Colchicine for Acute Pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design amd rationale. J Cardiovasc Med (Hagerstown). 2007;8(8):613–7.PubMedCrossRef
101.
Imazio M, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165(17):1987–91.PubMedCrossRef
102.
Imazio M, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409–14.PubMedCrossRef
103.
Imazio M, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383(9936):2232–7.PubMedCrossRef
104.
Nidorf SM, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.PubMedCrossRef
105.
Tardif J-C, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.PubMedCrossRef
106.
Lachmann HJ, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416–25.PubMedCrossRef
107.
Ruperto N, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396–406.PubMedCrossRef
108.
Ridker PM, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126(23):2739–48.PubMedCrossRef
109.
Ridker PM, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMedCrossRef
110.
Wada Y, et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol. 2023;82(4):279–85.PubMedCrossRef
111.
112.
113.
114.
Bozkurt B, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103(8):1044–7.PubMedCrossRef
115.
Chung ES, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.PubMedCrossRef
116.
Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging Clinical Data. J Inflamm Res. 2020;13:519–31.PubMedPubMedCentralCrossRef
117.
Herrera-deGuise C, et al. JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne). 2023;10:1089099.PubMedCrossRef
118.
Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–26.PubMedCrossRef
119.
Maksimović R, et al. Cardiac imaging in rheumatic diseases. Rheumatology (Oxford). 2006;45(Suppl 4):iv26–31.PubMedCrossRef
120.
Adler Y, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the diagnosis and management of Pericardial diseases of the European Society of Cardiology (ESC)endorsed by: the European Association for Cardio-thoracic surgery (EACTS). Eur Heart J. 2015;36(42):p2921–2964.CrossRef
121.
Ikonomidis I, et al. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clin Res Cardiol. 2019;108(10):1093–101.PubMedCrossRef
122.
Ikonomidis I, et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009;95(18):1502–7.PubMedCrossRef
123.
124.
Weber BN, et al. Impaired coronary Vasodilator Reserve and adverse prognosis in patients with systemic inflammatory disorders. JACC Cardiovasc Imaging. 2021;14(11):2212–20.PubMedPubMedCentralCrossRef
125.
Feher A, et al. Association between Impaired Myocardial Flow Reserve on < sup > 82 rubidium Positron Emission Tomography Imaging and adverse events in patients with autoimmune rheumatic disease. Volume 14. Circulation: Cardiovascular Imaging; 2021. p. e012208. 9.
126.
Nishiyama Y, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47(10):1571–6.PubMed
127.
128.
Youssef G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53(2):241–8.PubMedCrossRef
129.
Chareonthaitawee P, et al. Joint SNMMI-ASNC Expert Consensus Document on the role of (18)F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med. 2017;58(8):1341–53.PubMedPubMedCentralCrossRef
130.
McCabe JJ, et al. Carotid plaque inflammation imaged by PET and prediction of recurrent stroke at 5 years. Neurology. 2021;97(23):e2282–91.PubMedCrossRef
131.
Nensa F, et al. Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl Cardiol. 2018;25(3):785–94.PubMedCrossRef
132.
Goitein O, et al. Acute myocarditis: noninvasive evaluation with cardiac MRI and transthoracic echocardiography. AJR Am J Roentgenol. 2009;192(1):254–8.PubMedCrossRef
133.
Motoyama S, et al. Plaque characterization by Coronary computed Tomography Angiography and the likelihood of Acute coronary events in Mid-term Follow-Up. J Am Coll Cardiol. 2015;66(4):337–46.PubMedCrossRef
134.
Puchner SB, et al. High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014;64(7):684–92.PubMedPubMedCentralCrossRef
135.
Sagris M, et al. Pericoronary fat attenuation index-a new imaging biomarker and its diagnostic and prognostic utility: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2022;23(12):e526–36.PubMedPubMedCentralCrossRef
136.
Mavrogeni S, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8(5):390–7.PubMedCrossRef
137.
Mavrogeni S, Manoussakis MN. Myocarditis and subclavian stenosis in Takayasu arteritis. Int J Cardiol. 2011;148(2):223–4.PubMedCrossRef
138.
Mewton N, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891–903.PubMedCrossRef
139.
Tonet E et al. Coronary microvascular dysfunction: PET, CMR and CT Assessment. J Clin Med, 2021. 10(9).
140.
Puntmann VO, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging. 2013;6(2):295–301.PubMedCrossRef
141.
Bohnen S et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent-onset heart failure. Circ Cardiovasc Imaging, 2015. 8(6).
142.
143.
Mavrogeni S, et al. Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. Lupus. 2018;27(4):564–71.PubMedCrossRef
144.
Mavrogeni S, Bratis K, Kolovou G. Pathophysiology of Q waves in II, III, avF in systemic lupus erythematosus. Evaluation using cardiovascular magnetic resonance imaging. Lupus. 2012;21(8):821–9.PubMedCrossRef
145.
Mavrogeni S, et al. Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases. Int J Cardiol. 2017;236:151–6.PubMedCrossRef
Metadata
Title
The Emerging Specialty of Cardio-Rheumatology
Authors
Malek Nayfeh
Helene DiGregorio
Jean Michel Saad
Mouaz Al-Mallah
Mahmoud Al Rifai
Publication date
24-06-2024

Other articles of this Issue 9/2024

When Does Primary Prevention Encroach on Secondary Prevention?

Social Phenotyping for Cardiovascular Risk Stratification in Electronic Health Registries

  • Review

Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia

Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?

The Role of Social Determinants of Health in Atherosclerotic Cardiovascular Disease

  • Review

A Potential Role for MAGI-1 in the Bi-Directional Relationship Between Major Depressive Disorder and Cardiovascular Disease

  • Review

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases
Image Credits